Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 31Melanoma 20Neoplasms 13Breast Neoplasms 11Pancreatic Neoplasms 9Lung Neoplasms 9Head and Neck Neoplasms 9Triple Negative Breast Neoplasms 8Stomach Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Ovarian Neoplasms 8Neoplasm Metastasis 8Colorectal Neoplasms 7Carcinoma, Renal Cell 7Carcinoma, Hepatocellular 6Prostatic Neoplasms 4Hodgkin Disease 4Glioblastoma 4Carcinoma, Transitional Cell 4Carcinoma 4Uterine Cervical Neoplasms 3Liver Neoplasms 3Kidney Neoplasms 3Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Adenocarcinoma 3Small Cell Lung Carcinoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasms, Squamous Cell 2Mesothelioma 2

Interventions

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Cyclophosphamide 2pembrolizumab 1Vincristine 1Prednisone 1Interleukin-21 1Etoposide 1Doxorubicin 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Neoplasms, Experimental × pembrolizumab × Clear all
NCT05296772 2023-09-06

Phase 1 First-in-human Study of JS014

Anwita Biosciences

Phase 1 Unknown
60 enrolled
Lymphoid

Lymphoma, Neoplasms, Neoplasms, Experimental

Data powered by HemOnc (CC BY 4.0) Colophon âš¡